Advertisement

First-Line Therapy for Anaplastic Thyroid Cancer: Operation Versus Medical Management

  • Shabirhusain Abadin
  • Paritosh Suman
  • Jessica Hwang
  • Anu Thakrar
  • Subhash Patel
Chapter
Part of the Difficult Decisions in Surgery: An Evidence-Based Approach book series (DDSURGERY)

Abstract

Anaplastic thyroid cancer (ATC) is a highly lethal disease. First-line therapy for a patient diagnosed with this disease includes surgical resection or chemoradiation. Due to variable treatment and its rarity, there is a paucity of prospective and/or randomized controlled literature studying the initial therapy for patients diagnosed with ATC. To understand which therapy is more appropriate in terms of survival and quality of life, we evaluated the available literature and our own institutional experience with the management of ATC for recommendations regarding this topic. This chapter provides a summary of the pertaining literature and offers recommendations based on these sources for first-line management of a patient with newly diagnosed ATC.

Keywords

Anaplastic thyroid cancer Carcinoma Thyroidectomy Surgery Chemoradiation Radiotherapy Chemotherapy 

References

  1. 1.
    Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010;22(6):486–97.CrossRefGoogle Scholar
  2. 2.
    Keutgen XM, Sadowski SM, Kebebew E. Management of anaplastic thyroid cancer. Gland Surg. 2015;4(1):44–51.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Derbel O, Limem S, Segura-Ferlay C, Lifante JC, Carrie C, Peix JL, et al. Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer. 2011;11:469.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013;23(5):600–4.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim TY, Kim KW, Jung TS, Kim JM, Kim SW, Chung KW, et al. Prognostic factors for Korean patients with anaplastic thyroid carcinoma. Head Neck. 2007;29(8):765–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H, Matsuzuka F, et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck. 1996;18(1):36–41.CrossRefPubMedGoogle Scholar
  8. 8.
    Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol. 2002;9(1):57–64.CrossRefPubMedGoogle Scholar
  9. 9.
    Besic N, Hocevar M, Zgajnar J, Pogacnik A, Grazio-Frkovic S, Auersperg M. Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients. Langenbecks Arch Surg. 2005;390(3):203–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Ito K, Hanamura T, Murayama K, Okada T, Watanabe T, Harada M, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck. 2012;34(2):230–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Besic N, Gazic B. Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution. Thyroid. 2013;23(6):709–13.CrossRefPubMedGoogle Scholar
  12. 12.
    Kihara M, Miyauchi A, Yamauchi A, Yokomise H. Prognostic factors of anaplastic thyroid carcinoma. Surg Today. 2004;34(5):394–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab. 2012;97(8):2566–72.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104–39.CrossRefPubMedGoogle Scholar
  15. 15.
    Passler C, Scheuba C, Prager G, Kaserer K, Flores JA, Vierhapper H, et al. Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg. 1999;384(3):284–93.CrossRefPubMedGoogle Scholar
  16. 16.
    Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001;91(12):2335–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid. 2011;21(11):1183–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiother Oncol. 2009;92(1):100–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Tan RK, Finley RK 3rd, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck. 1995;17(1):41–7. discussion 7–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang ZM, Xu ZG, Tang PZ, Xue LY, Lu N. A retrospective analysis of anaplastic thyroid carcinoma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006;28(3):322–4.PubMedGoogle Scholar
  21. 21.
    Holting T, Meybier H, Buhr H. Problems of tracheotomy in locally invasive anaplastic thyroid cancer. Langenbecks Arch Chir. 1989;374(2):72–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Holting T, Meybier H, Buhr H. Status of tracheotomy in treatment of the respiratory emergency in anaplastic thyroid cancer. Wien Klin Wochenschr. 1990;102(9):264–6.PubMedGoogle Scholar
  23. 23.
    Shaha AR. Airway management in anaplastic thyroid carcinoma. Laryngoscope. 2008;118(7):1195–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Wein RO, Weber RS. Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg. 2011;19(2):113–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer. 2006;107(8):1786–92.CrossRefPubMedGoogle Scholar
  26. 26.
    Levendag PC, De Porre PM, van Putten WL. Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys. 1993;26(1):125–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Sherman EJ, Lim SH, Ho AL, Ghossein RA, Fury MG, Shaha AR, et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol. 2011;101(3):425–30.CrossRefPubMedGoogle Scholar
  28. 28.
    Nutting CM, Convery DJ, Cosgrove VP, Rowbottom C, Vini L, Harmer C, et al. Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland. Radiother Oncol. 2001;60(2):173–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Posner MD, Quivey JM, Akazawa PF, Xia P, Akazawa C, Verhey LJ. Dose optimization for the treatment of anaplastic thyroid carcinoma: a comparison of treatment planning techniques. Int J Radiat Oncol Biol Phys. 2000;48(2):475–83.CrossRefPubMedGoogle Scholar
  30. 30.
    Dandekar P, Harmer C, Barbachano Y, Rhys-Evans P, Harrington K, Nutting C, et al. Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys. 2009;74(2):518–21.CrossRefPubMedGoogle Scholar
  31. 31.
    De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(4):1137–43.CrossRefPubMedGoogle Scholar
  32. 32.
    Wong CS, Van Dyk J, Simpson WJ. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol. 1991;20(1):3–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86(12):1848–53.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Pudney D, Lau H, Ruether JD, Falck V. Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review. Thyroid. 2007;17(12):1243–50.CrossRefPubMedGoogle Scholar
  35. 35.
    Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol. 2001;27(3):260–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Sugino K, Ito K, Mimura T, Nagahama M, Fukunari N, Kubo A, et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery. 2002;131(3):245–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Heron DE, Karimpour S, Grigsby PW. Anaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups. Am J Clin Oncol. 2002;25(5):442–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Troch M, Koperek O, Scheuba C, Dieckmann K, Hoffmann M, Niederle B, et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab. 2010;95(9):E54–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Nehs MA, Nagarkatti S, Nucera C, Hodin RA, Parangi S. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery. 2010;148(6):1154–62. discussion 62.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Seto A, Sugitani I, Toda K, Kawabata K, Takahashi S, Saotome T. Chemotherapy for anaplastic thyroid cancer using docetaxel and cisplatin: report of eight cases. Surg Today. 2015;45(2):221–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Guerra A, Di Crescenzo V, Garzi A, Cinelli M, Carlomagno C, Tonacchera M, et al. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surg. 2013;13(Suppl 2):S44.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16(1):17–44.CrossRefPubMedGoogle Scholar
  43. 43.
    Ragazzi M, Ciarrocchi A, Sancisi V, Gandolfi G, Bisagni A, Piana S. Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol. 2014;2014:790834.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Pinto N, Black M, Patel K, Yoo J, Mymryk JS, Barrett JW, et al. Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer. J Oncol. 2014;2014:936285.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, et al. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology. 2012;153(2):985–94.CrossRefPubMedGoogle Scholar
  46. 46.
    Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20(9):975–80.CrossRefPubMedGoogle Scholar
  47. 47.
    Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012;97(9):3179–84.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Lim SM, Chang H, Yoon MJ, Hong YK, Kim H, Chung WY, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol. 2013;24(12):3089–94.CrossRefPubMedGoogle Scholar
  49. 49.
    Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, et al. Efatutazone, an oral PPAR-gamma agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013;98(6):2392–400.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014;24(2):232–40.CrossRefPubMedGoogle Scholar
  51. 51.
    Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009;19(3):233–40.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, et al. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med. 2013;5(166):166ra3.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Shabirhusain Abadin
    • 1
  • Paritosh Suman
    • 2
  • Jessica Hwang
    • 3
  • Anu Thakrar
    • 4
  • Subhash Patel
    • 1
  1. 1.John H. Stroger, Jr. Hospital of Cook County, Department of SurgeryChicagoUSA
  2. 2.NorthShore University HealthSystem/John H. Stroger Hospital of Cook County, Department of SurgeryEvanstonUSA
  3. 3.John H. Stroger, Jr. Hospital of Cook County, Department of Endocrinology and DiabetesChicagoUSA
  4. 4.Department of Radiation OncologyJohn H. Stroger, Jr. Hospital of Cook CountyChicagoUSA

Personalised recommendations